Diabetes, Vol 47, Issue 1 130-133, Copyright © 1998 by American Diabetes Association

ARTICLES

Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients

L Cominacini, U Garbin, A Fratta Pasini, M Campagnola, A Davoli, E Foot, G Sighieri, AM Sironi, V Lo Cascio and E Ferrannini
Istituto di Semeiotica e Nefrologia Medica, University of Verona, Italy. comina@medicinad.univr.it

Troglitazone, an oral antidiabetic agent with antioxidant properties, has previously been shown to increase the resistance of LDL to oxidation in vitro and in vivo in healthy volunteers. In a randomized, placebo-controlled, parallel-group study in 29 patients with NIDDM, we tested the effect of troglitazone (200 mg once daily) on the resistance of LDL to oxidation and on circulating levels of preformed lipid hydroperoxides and the adhesion molecule E-selectin. Resistance of LDL to oxidation was assessed by measuring 1) fluorescence development induced by copper treatment (lag phase), and 2) amount of thiobarbituric acid-reactive substances (TBARS) generated by incubation with umbilical vein endothelial cells. At 8 weeks, the lag phase was increased by 23% (P < 0.01 by analysis of covariance [ANCOVA]) in the patients receiving troglitazone (n = 18) compared with the group receiving placebo (n = 11). At the same time, TBARS were 3.63 +/- 0.10 nmol/l (vs. 5.32 +/- 0.10 nmol/l in the placebo group, P = 0.009), LDL hydroperoxide concentration was reduced from 1.48 +/- 0.03 to 1.19 +/- 0.03 ng/mg (no change in the placebo group, P < 0.01), and plasma E-selectin levels decreased from 56.5 +/- 2.33 to 43.7 +/- 1.77 microg/l (no change in the placebo group, P < 0.01). In NIDDM, troglitazone may slow down the development of atherosclerosis by modifying LDL-related atherogenic events.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. J Deckelbaum, T. S Worgall, and T. Seo n-3 Fatty acids and gene expression Am. J. Clinical Nutrition, June 1, 2006; 83(6): S1520 - 1525S. [Abstract] [Full Text] [PDF]

				J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart Peroxisome Proliferator-Activated Receptor {gamma} Ligands Stimulate Endothelial Nitric Oxide Production Through Distinct Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Mechanisms Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1810 - 1816. [Abstract] [Full Text] [PDF]

				J. B. Meigs, F. B. Hu, N. Rifai, and J. E. Manson Biomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus JAMA, April 28, 2004; 291(16): 1978 - 1986. [Abstract] [Full Text] [PDF]

				J. S. Sidhu, D. Cowan, and J.-C. Kaski The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1757 - 1763. [Abstract] [Full Text] [PDF]

				M. B. Davidson Is Treatment of Insulin Resistance Beneficial Independent of Glycemia? Diabetes Care, November 1, 2003; 26(11): 3184 - 3186. [Full Text] [PDF]

				J. P.H. van Wijk, E. J.P. de Koning, E. P. Martens, and T. J. Rabelink Thiazolidinediones and Blood Lipids in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1744 - 1749. [Abstract] [Full Text] [PDF]

				V. R. Aroda and R. R. Henry Thiazolidinediones: Potential Link Between Insulin Resistance and Cardiovascular Disease Diabetes Spectr, April 1, 2003; 16(2): 120 - 125. [Abstract] [Full Text] [PDF]

				N. Marx, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, H. Scharnagl, V. Hombach, and W. Koenig Antidiabetic PPAR{gamma}-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 283 - 288. [Abstract] [Full Text] [PDF]

				N. Marx PPAR{gamma} and Vascular Inflammation: Adding Another Piece to the Puzzle Circ. Res., September 6, 2002; 91(5): 373 - 374. [Full Text] [PDF]

				J. Calles-Escandon and M. Cipolla Diabetes and Endothelial Dysfunction: A Clinical Perspective Endocr. Rev., February 1, 2001; 22(1): 36 - 52. [Abstract] [Full Text]

				A. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca Nonhypoglycemic Effects of Thiazolidinediones Ann Intern Med, January 2, 2001; 134(1): 61 - 71. [Abstract] [Full Text] [PDF]

				S. Devaraj and I. Jialal Low-Density Lipoprotein Postsecretory Modification, Monocyte Function, and Circulating Adhesion Molecules in Type 2 Diabetic Patients With and Without Macrovascular Complications : The Effect of {alpha}-Tocopherol Supplementation Circulation, July 11, 2000; 102(2): 191 - 196. [Abstract] [Full Text] [PDF]

				A. Quinones-Galvan, A. M. Sironi, S. Baldi, F. Galetta, U. Garbin, A. Fratta-Pasini, L. Cominacini, and E. Ferrannini Evidence That Acute Insulin Administration Enhances LDL Cholesterol Susceptibility to Oxidation in Healthy Humans Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2928 - 2932. [Abstract] [Full Text] [PDF]

				N. Marx, U. Schonbeck, M. A. Lazar, P. Libby, and J. Plutzky Peroxisome Proliferator-Activated Receptor Gamma Activators Inhibit Gene Expression and Migration in Human Vascular Smooth Muscle Cells Circ. Res., November 30, 1998; 83(11): 1097 - 1103. [Abstract] [Full Text] [PDF]